Evidence map›Paper›PMID 27618557›Full record

ReviewBiochemistry2016

MST1/MST2 Protein Kinases: Regulation and Physiologic Roles.

Jacob A Galan, Joseph Avruch

Abstract readReview
In one paragraph

Review in Biochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 94 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. MST1/2 in inflammation and immunity.Cell adhesion & migration · 2023
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Hippo Signaling: Advances in Potential Therapeutic Targets for Sinoatrial Node Disorders.International journal of drug discovery and pharmacology · 2023
    Article
  19. Extracellular matrix stiffness regulates degradation of MST2 via SCFBiochimica et biophysica acta. General subjects · 2022
    Article
  20. Effect of Inactivation ofJournal of the Endocrine Society · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jacob A GalanDepartment of Molecular Biology, Massachusetts General Hospital , Boston, Massachusetts 02114, United States.
Joseph AvruchDepartment of Molecular Biology, Massachusetts General Hospital , Boston, Massachusetts 02114, United States.
Massachusetts General Hospital · US

Funding

TRAINING PROGRAM IN ENDOCRINOLOGY AND DIABETEST32DK007028 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Karen K Miller · 1986 to 2026
$18.5M
PHOSPHOPEPTIDE METABOLISM IN ADIPOCYTESR37DK017776 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI AVRUCH, JOSEPH · 1999 to 2018
$9.3M
Decoding the MST1 and MST2 kinases in cellular physiology and tumor suppressionR01CA136567 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI AVRUCH, JOSEPH, EL-BARDEESY, NABEEL · 2010 to 2014
$3.1M
NCI NIH HHS R01 CA136567NIDDK NIH HHS R37 DK017776NIDDK NIH HHS T32 DK007028
6 · The paper itself

Abstract

The MST1 and MST2 protein kinases comprise the GCK-II subfamily of protein kinases. In addition to their amino-terminal kinase catalytic domain, related to that of the Saccharomyces cerevisiae protein kinase Ste20, their most characteristic feature is the presence near the carboxy terminus of a unique helical structure called a SARAH domain; this segment allows MST1/MST2 to homodimerize and to heterodimerize with the other polypeptides that contain SARAH domains, the noncatalytic polypeptides RASSF1-6 and Sav1/WW45. Early studies emphasized the potent ability of MST1/MST2 to induce apoptosis upon being overexpressed, as well as the conversion of the endogenous MST1/MST2 polypeptides to constitutively active, caspase-cleaved catalytic fragments during apoptosis initiated by any stimulus. Later, the cleaved, constitutively active form of MST1 was identified in nonapoptotic, quiescent adult hepatocytes as well as in cells undergoing terminal differentiation, where its presence is necessary to maintain those cellular states. The physiologic regulation of full length MST1/MST2 is controlled by the availability of its noncatalytic SARAH domain partners. Interaction with Sav1/WW45 recruits MST1/MST2 into a tumor suppressor pathway, wherein it phosphorylates and activates the Sav1-bound protein kinases Lats1/Lats2, potent inhibitors of the Yap1 and TAZ oncogenic transcriptional regulators. A constitutive interaction with the Rap1-GTP binding protein RASSF5B (Nore1B/RAPL) in T cells recruits MST1 (especially) and MST2 as an effector of Rap1's control of T cell adhesion and migration, a program crucial to immune surveillance and response; loss of function mutation in human MST1 results in profound immunodeficiency. MST1 and MST2 are also regulated by other protein kinases, positively by TAO1 and negatively by Par1, SIK2/3, Akt, and cRaf1. The growing list of candidate MST1/MST2 substrates suggests that the full range of MST1/MST2's physiologic programs and contributions to pathophysiology remains to be elucidated.

Indexed as

AnimalsApoptosisCatalysisEnzyme ActivationHumansLiverMitosisPhosphorylationProtein ConformationProtein KinasesReactive Oxygen SpeciesSubstrate SpecificityTyrosineProtein KinasesReactive Oxygen SpeciesTyrosine

Identifiers

PMID27618557
PMCPMC5479320
OpenAlexW2519289960

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.